Autoreactive Plasmablasts After B Cell Depletion With Rituximab and Relapses in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Arthritis & Rheumatology · 2023
DOI: 10.1002/art.42388 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, 2023. Verfasst von Alvise Berti und 21 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary & Critical Care Medicine, Thoracic Disease Research Unit, Mayo Clinic, Rochester, Minnesota, and Center for Medical Sciences (C…. Hauptthemen laut MEDLINE: Antibodies, Antineutrophil Cytoplasmic, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAID NIH HHS, NIAMS NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Objective
Autoreactive B cells are responsible for antineutrophil cytoplasmic antibody (ANCA) production in ANCA‐associated vasculitis (AAV). Rituximab (RTX) depletes circulating B cells, including autoreactive B cells. We aimed to evaluate changes and associations with relapse of the circulating autoreactive B cell pool following therapeutic B cell depletion in AAV.
Methods
Sequential flow cytometry was performed on 148 samples of peripheral blood mononuclear cells from 23 patients with proteinase 3 (PR3)–ANCA–positive AAV who were treated with RTX for remission induction and monitored after stopping therapy during long‐term follow‐up in a prospective clinical trial. PR3 was used as a ligand to target autoreactive PR3‐specific (PR3+) B cells. B cell recurrence was considered as the first blood sample with ≥10 B cells/μl after RTX treatment.
Results
At B cell recurrence, PR3+ B cell frequency among B cells was higher than baseline ( P < 0.01). Within both PR3+ and total B cells, frequencies of transitional and naive subsets were higher at B cell recurrence than at baseline, while memory subsets were lower ( P < 0.001 for all comparisons). At B cell recurrence, frequencies of B cells and subsets did not differ between patients who experienced relapse and patients who remained in remission. In contrast, the plasmablast frequency within the PR3+ B cell pool was higher in patients who experienced relapse and associated with a shorter time to relapse. Frequencies of PR3+ plasmablasts higher than baseline were more likely to be found in patients who experienced relapse within the following 12 months compared to those in sustained remission ( P < 0.05).
Conclusion
The composition of the autoreactive B cell pool varies significantly following RTX treatment in AAV, and early plasmablast enrichment within the autoreactive pool is associated with future relapses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Pulmonary & Critical Care Medicine, Thoracic Disease Research Unit, Mayo Clinic, Rochester, Minnesota, and Center for Medical Sciences (CISMed), Department of Cellular, Computational and Integrative Biology…
- Université de Bretagne Occidendale, Brest, Bretagne, France.
- Division of Rheumatology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
- Division of Pulmonary & Critical Care Medicine, Thoracic Disease Research Unit, Mayo Clinic, Rochester, Minnesota.
- Division of Nephrology & Hypertension, Mayo Clinic, Rochester, Minnesota.
- Department of Rheumatology and Clinical Immunology, University of Groningen, Groningen, The Netherlands.
ORCID-Profile: Alvise Berti, Sophie Hillion, Maximilian F Konig, Marta Casal Moura, Paul A Monach, Robert F Spiera, John H Stone, Jacques-Olivier Pers, Ulrich Specks, Divi Cornec
Förderung
- NIAID NIH HHS
- NIAMS NIH HHS
- National Institute of Allergy and Infectious Diseases
- Vasculitis Foundation
- Mayo Foundation for Medical Education and Research
- Foundation for the National Institutes of Health
Zitieren
APA
Berti, A., Hillion, S., Konig, M. F., Moura, M. C., Hummel, A. M., Carmona, E., Peikert, T., Fervenza, F. C., Kallenberg, C. G. M., Langford, C. A., Merkel, P. A., Monach, P. A., Seo, P., Spiera, R. F., Brunetta, P., St Clair, E. W., Harris, K. M., Stone, J. H., Grandi, G., …, & Cornec, D. (2023). Autoreactive Plasmablasts After B Cell Depletion With Rituximab and Relapses in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. Arthritis & Rheumatology. https://doi.org/10.1002/art.42388
Vancouver
Berti A, Hillion S, Konig MF, Moura MC, Hummel AM, Carmona E, et al. Autoreactive Plasmablasts After B Cell Depletion With Rituximab and Relapses in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. Arthritis & Rheumatology. 2023. doi:10.1002/art.42388
BibTeX
@article{Berti2023,
author = {Berti, Alvise and Hillion, Sophie and Konig, Maximilian F and Moura, Marta Casal and Hummel, Amber M and Carmona, Eva and Peikert, Tobias and Fervenza, Fernando C and Kallenberg, Cees G M and Langford, Carol A and Merkel, Peter A and Monach, Paul A and Seo, Philip and Spiera, Robert F and Brunetta, Paul and St Clair, E William and Harris, Kristina M and Stone, John H and Grandi, Guido and Pers, Jacques-Olivier and Specks, Ulrich and Cornec, Divi},
title = {Autoreactive Plasmablasts After B Cell Depletion With Rituximab and Relapses in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis},
journal = {Arthritis & Rheumatology},
year = {2023},
doi = {10.1002/art.42388}
}
EUVIMED